GAGANDEEP KAUR: Open Payments
NPI 1639734700 · CONCORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$437 in 18 payments from 11 companies in 2025. Trend: 2023 $450 · 2024 $0 · 2025 $437
Food & beverage: $437
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $121 |
| ABBVIE INC. | 3 | $66 |
| Lundbeck LLC | 2 | $46 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $31 |
| Novo Nordisk Inc | 1 | $31 |
| Exact Sciences Corporation | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| PFIZER INC. | 1 | $19 |
Products named: CAPLYTA, REXULTI, QULIPTA, HETLIOZ, XIFAXAN, Wegovy, VRAYLAR, Cologuard Collection Kit.
Industry payments across CA — which companies pay providers there.
